Pasar al contenido principal

ACTIVACION DE PPARB/D Y HRI:EXPLORANDO NUEVOS MECANISMOS COMPENSATORIOS PARA EL TRATAMIENTO DE LA INFLAMACION, LA RESISTENCIA A LA INSULINA Y LA ESTEATOHEPATITIS NO ALCOHOLICA

RTI2018-093999-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CHOP upregulation and dysregulation of the mature form of the SNAT2 amino acid transporter in the placentas from small for gestational age newborns

  • Barroso, Emma
  • Díaz, Marta
  • Reguera, Ana Cristina
  • Peyman, Mona
  • Balsinde, Jesús
  • Jurado-Aguilar, Javier
  • Zhang, Meijian
  • Rostami, Adel
  • Palomer, Xavier
  • Ibáñez, Lourdes
  • Vázquez-Carrera, Manuel
[Background]: The placentas from newborns that are small for gestational age (SGA; birth weight < -2 SD for gestational age) may display multiple pathological characteristics. A key determinant of fetal growth and, therefore, birth weight is placental amino acid transport, which is under the control of the serine/threonine kinase mechanistic target of rapamycin (mTOR). The effects of endoplasmic reticulum (ER) stress on the mTOR pathway and the levels of amino acid transporters are not well established. [Methods]: Placentas from SGA and appropriate for gestational age (AGA) newborns and the human placental BeWo cell line exposed to the ER stressor tunicamycin were used. [Results]: We detected a significant increase in the levels of C/EBP homologous protein (CHOP) in the placentas from SGA newborns compared with those from AGA newborns, while the levels of other ER stress markers were barely affected. In addition, placental mTOR Complex 1 (mTORC1) activity and the levels of the mature form of the amino acid transporter sodium-coupled neutral amino acid transporter 2 (SNAT2) were also reduced in the SGA group. Interestingly, CHOP has been reported to upregulate growth arrest and DNA damage-inducible protein 34 (GADD34), which in turn suppresses mTORC1 activity. The GADD34 inhibitor guanabenz attenuated the increase in CHOP protein levels and the reduction in mTORC1 activity caused by the ER stressor tunicamycin in the human placental cell line BeWo, but it did not recover mature SNAT2 protein levels, which might be reduced as a result of defective glycosylation. [Conclusions]: Collectively, these data reveal that GADD34A activity and glycosylation are key factors controlling mTORC1 signaling and mature SNAT2 levels in trophoblasts, respectively, and might contribute to the SGA condition., This study was partly supported by the grants RTI2018-093999-B-I00 and PID2021-122116OB-I00 (M.V.-C.) from MCIN/AEI/10.13039/501100011033 and “ERDF, A Way of Making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ

  • Zhang, Meijian
  • Barroso, Emma
  • Ruart, Maria
  • Peña, Lucía
  • Peyman, Mona
  • Aguilar-Recarte, David
  • Montori-Grau, Marta
  • Rada, Patricia
  • Cugat, Clara
  • Montironi, Carla
  • Zarei, Mohammad
  • Jurado-Aguilar, Javier
  • Camins, Antoni
  • Balsinde, Jesús
  • Valverde, Ángela M.
  • Wahli, Walter
  • Palomer, Xavier
  • Vázquez-Carrera, Manuel
Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR)α and β/δ agonist that has reached a phase III clinical trial for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we examined the effects of elafibranor in mice fed a choline-deficient high-fat diet (CD-HFD), a model of metabolic dysfunction-associated steatohepatitis (MASH) that presents obesity and insulin resistance. Our findings revealed that elafibranor treatment ameliorated steatosis, inflammation, and fibrogenesis in the livers of CD-HFD-fed mice. Unexpectedly, elafibranor also increased the levels of the epithelial-mesenchymal transition (EMT)-promoting protein S100A4 via PPARβ/δ activation. The increase in S100A4 protein levels caused by elafibranor was accompanied by changes in the levels of markers associated with the EMT program. The S100A4 induction caused by elafibranor was confirmed in the BRL-3A rat liver cells and a mouse primary hepatocyte culture. Furthermore, elafibranor reduced the levels of ASB2, a protein that promotes S100A4 degradation, while ASB2 overexpression prevented the stimulating effect of elafibranor on S100A4. Collectively, these findings reveal an unexpected hepatic effect of elafibranor on increasing S100A4 and promoting the EMT program., This study was partly supported by the grants RTI2018-093999-B-I00 and PID2021-122116OB-I00 (M.V-C.), PID2021-122766OB-I00 (A.M.V.), and PID2019-105989RB-I00 (J.B.) from MCIN/AEI/10.13039/501100011033 and “ERDF, A Way of Making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. Support was also received from the CERCA Programme/Generalitat de Catalunya. Meijian Zhang was supported by a grant from the China Scholarship Council (CSC) (202007565030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase-targeting PROTAC activates AMPK and inhibits endoplasmic reticulum stress

  • Peyman, Mona
  • Barroso, Emma
  • Turcu, Andreea L.
  • Estrany Jr., Francesc
  • Smith, Dáire
  • Jurado-Aguilar, Javier
  • Rada, Patricia
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Valverde, Ángela M.
  • Palomer, Xavier
  • Galdeano, Carles
  • Vázquez, Santiago
  • Vázquez-Carrera, Manuel
Soluble epoxide hydrolase (sEH) is a drug target with the potential for therapeutic utility in the areas of inflammation, neurodegenerative disease, chronic pain, and diabetes, among others. Proteolysis-targeting chimeras (PROTACs) molecules offer new opportunities for targeting sEH, due to its capacity to induce its degradation. Here, we describe that the new ALT-PG2, a PROTAC that degrades sEH protein in the human hepatic Huh-7 cell line, in isolated mouse primary hepatocytes, and in the liver of mice. Remarkably, sEH degradation caused by ALT-PG2 was accompanied by an increase in the phosphorylated levels of AMP-activated protein kinase (AMPK), while phosphorylated extracellular-signal-regulated kinase 1/2 (ERK1/2) was reduced. Consistent with the key role of these kinases on endoplasmic reticulum (ER) stress, ALT-PG2 attenuated the levels of ER stress and inflammatory markers. Overall, the findings of this study indicate that targeting sEH with degraders is a promising pharmacological strategy to promote AMPK activation and to reduce ER stress and inflammation., This study was partly supported by grants RTI2018-093999-B-100 and PID2021-122116OB-I00 (M.V-C.), PID2020-118127RB-I00 (S.V.), PID2021-127693OB-I00 (C.G.) and PID2021-122766OB-I00 (A.M.V.) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) is a Carlos III Health Institute project. CERCA Programme/Generalitat de Catalunya. Partial support was provided by NIH – NIEHS (RIVER Award) R35 ES030443-01, NIH – NIEHS (Superfund Award) P42 ES004699 and NIH Counter Act Award U54 NS127758 (B.H.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

  • Codony, Sandra
  • Calvó-Tusell, Carla
  • Valverde, Elena
  • Osuna, Sílvia
  • Morisseau, Christophe
  • Loza, M. Isabel
  • Brea, José
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Pizarro-Delgado, Javier
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Vázquez-Carrera, Manuel
  • Hammock, Bruce D.
  • Feixas, Ferran
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093999-B-100 to M. V.-C., RTI2018-093955-B-C21 to M.I.R.-F., SAF2016-77703-C2 to M.P. and C.S., PGC2018- 102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spain EIT Health (Proof of concept 2016), the European Regional Development Fund (ERDF), the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-Net- MoDEzyme to S.O.), and the European Community (MSCA-IF- 2014-EF-661160-MetAccembly to F.F.). S.C. and E.V. acknowledge the PhD fellowships from the Universitat de Barcelona (APIF grant) and the Institute of Biomedicine of the University of Barcelona (IBUB), respectively. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Peer reviewed